After hours:
| Previous Close | 4.3200 |
| Open | 4.3700 |
| Bid | 4.3100 x 100 |
| Ask | 4.5700 x 100 |
| Day's Range | 4.3200 - 4.5798 |
| 52 Week Range | 4.0000 - 19.2980 |
| Volume | |
| Avg. Volume | 104,935 |
| Market Cap | 143.747M |
| Beta (5Y Monthly) | 1.76 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.9800 |
| Earnings Date | Nov 07, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.20 |
Business WirePepGen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Senior Vice President, Clinical Development
BOSTON, November 21, 2024--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced it awarded an inducement grant under PepGen’s 2024 Inducement Plan as a material inducement to employment to its newly appointed Senior Vice President, Clinical Development, Steve Han, MD, PhD, MMSc.
Business WirePepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights
BOSTON, November 07, 2024--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended September 30, 2024.
